FEB 10, 2015 9:00 AM PST

Primary HPV Cervical Cancer Screening: Supporting data and guidance updates

Speaker

Abstract
Date: Tuesday, February 10th, 2015
Time: 9:00AM PST, 12:00PM EST

For the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology -- if it is negative, women are rescreen in three years and if positive, are referred to follow-up examinations. Although this strategy has led to a tremendous reduction in the incidence of cervical cancer, some significant limitations exist. Cytology has low sensitivity for cervical cancer pre-cursors, has low reproducibility, and does not adequately assess long-term risk. HPV testing added to cytology as a co-test for women 30 years and older increases the sensitivity of cytology and addresses many of its limitation, but also significantly contributes to the complexity of management. In 2014, the FDA approved the first hrHPV test for the use as a primary test for cervical cancer screening for women 25 years and older. More recently, interim guidance was co-published by the Society of Gynecologic Oncology (SGO) and the American Society for Colposcopy and Cervical Pathology (ASCCP) on the use of primary hrHPV testing as an alternative to current US cytology-based cervical screening methods as it was found to provide greater reassurance of low CIN3+ risk than a negative cytology result. Additionally, due to the high prevalence of CIN3+ in women 25-29, for which cytology - the current standard of care - detected fewer than 50% of these cases, primary HPV testing could be imitated as early as age 25. Primary hrHPV screening is a significant scientific and clinical advance in cervical cancer screening as it provides improved reassurance of cancer risk following a negative result than cytology-based screening.

Learning objectives:
• Define HPV primary screening.
• Discuss key data around HPV primary screening.
• Describe new HPV primary screening and management guidance.

Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
JUN 03, 2021 8:00 AM PDT
JUN 03, 2021 8:00 AM PDT
Date: June 3, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Molecular combing provides unbiased quantification and characterization of DNA structure and dynamics by imaging single DN...
APR 21, 2021 5:00 PM CEST
APR 21, 2021 5:00 PM CEST
Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
Loading Comments...
Show Resources
Attendees
  • See more